Q-omics provides the consensus-scored CT75 profile across patient tissues and cancer cell-line models. CT75 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CT75 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, CT75 RNA expression shows 16,755 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, THCA, and LSCC as cancer lineages where CT75 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CT75 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CT75 survival associations across molecular data types. CT75 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CT75 RNA expression–survival associations across cancer types. High CT75 expression shows unfavorable associations in KIRC, UCEC and COAD, but favorable associations in HNSC, LUSC and ACC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CT75 RNA expression.
This table summarizes CT75 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for CT75. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CT75 shows lower tumor expression in THCA, KIRC and KICH and higher tumor expression in LUSC, HNSC and LUAD. The THCA box plot shows higher CT75 RNA expression in normal versus tumor tissue (log2 FC = −2.022, t-test p < 0.001).
This table shows molecular features associated with CT75 in patient tissues and cancer cell lines. In patient samples, CT75 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
